Running Oak Capital LLC Has $15.61 Million Position in IQVIA Holdings Inc. $IQV

Running Oak Capital LLC raised its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 20.3% in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 99,077 shares of the medical research company’s stock after acquiring an additional 16,735 shares during the quarter. Running Oak Capital LLC owned approximately 0.06% of IQVIA worth $15,614,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Everpar Advisors LLC raised its position in IQVIA by 4.6% during the 2nd quarter. Everpar Advisors LLC now owns 1,404 shares of the medical research company’s stock worth $221,000 after purchasing an additional 62 shares during the last quarter. Ballentine Partners LLC lifted its stake in shares of IQVIA by 4.9% in the first quarter. Ballentine Partners LLC now owns 1,477 shares of the medical research company’s stock worth $260,000 after acquiring an additional 69 shares during the period. Independent Advisor Alliance boosted its holdings in IQVIA by 4.2% in the first quarter. Independent Advisor Alliance now owns 1,801 shares of the medical research company’s stock valued at $318,000 after acquiring an additional 72 shares during the last quarter. Nemes Rush Group LLC raised its holdings in IQVIA by 15.0% during the 1st quarter. Nemes Rush Group LLC now owns 621 shares of the medical research company’s stock worth $109,000 after purchasing an additional 81 shares during the last quarter. Finally, Forte Capital LLC ADV lifted its position in shares of IQVIA by 0.3% in the 2nd quarter. Forte Capital LLC ADV now owns 26,809 shares of the medical research company’s stock worth $4,225,000 after purchasing an additional 92 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. UBS Group lifted their target price on shares of IQVIA from $185.00 to $225.00 and gave the stock a “buy” rating in a research note on Wednesday, July 23rd. Evercore ISI lifted their price objective on IQVIA from $170.00 to $180.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 9th. Redburn Partners set a $214.00 target price on IQVIA in a research report on Wednesday, September 3rd. Weiss Ratings reiterated a “hold (c)” rating on shares of IQVIA in a report on Saturday, September 27th. Finally, Jefferies Financial Group upgraded IQVIA from a “hold” rating to a “buy” rating and increased their price target for the stock from $195.00 to $225.00 in a report on Tuesday, September 9th. Eighteen equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $230.32.

Insider Activity

In related news, insider Keriann Cherofsky sold 549 shares of the company’s stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total value of $105,149.97. Following the sale, the insider owned 2,910 shares in the company, valued at $557,352.30. This represents a 15.87% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Eric Sherbet sold 5,800 shares of IQVIA stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the transaction, the insider owned 27,178 shares of the company’s stock, valued at $5,165,178.90. This trade represents a 17.59% decrease in their position. The disclosure for this sale can be found here. Insiders own 1.60% of the company’s stock.

IQVIA Trading Up 1.2%

NYSE IQV opened at $206.84 on Monday. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $237.34. The business has a 50 day moving average price of $187.90 and a 200-day moving average price of $167.44. The company has a market cap of $35.16 billion, a price-to-earnings ratio of 29.93, a P/E/G ratio of 2.27 and a beta of 1.32.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.04. The business had revenue of $4.02 billion during the quarter, compared to the consensus estimate of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. IQVIA’s revenue was up 5.3% compared to the same quarter last year. During the same quarter last year, the firm posted $2.64 EPS. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. As a group, equities analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.